March 31, 2021

UC San Diego welcomed new and returning students for Spring Quarter on March 24. Learn more in the Spring Plan about academics, including resumption of limited indoor instruction; screening and testing protocols after vaccination; new and returning student move-in guidelines and more.

We are in the early stages of an incremental return to campus. Because of your support in complying with county and campus safety precautions, we are able to expand the occupancy cap in research settings up to 50% beginning Apr. 1. Faculty and researchers who wish to return only to their private offices for individual work should complete the Employee Work Health Management form.

Thank you to all of our students who stayed local to take part in Spring Break events held on-campus and remotely. Every effort made to slow the spread makes a difference! We’d also like to recognize the dozens of staff members who made this inaugural event program possible. 

See a slideshow of the weeklong series of activities.

Answer: After your first vaccine dose you should be automatically scheduled for your second vaccine appointment in your MyUCSDChart. Please login to your MyStudentChart (students) or MyChart (employees) to confirm whether you have already been scheduled. If more than three days have passed since your first dose and you have not received any communication about your second dose, please contact us at rtl@ucsd.edu. 

Answer: According to the Centers for Disease Control and Prevention (CDC), we do not know how long protection lasts for those who are vaccinated. What we do know is that COVID-19 has caused very serious illness and death for some people. If you get COVID-19, you also risk giving it to loved ones who may get very sick. Getting a COVID-19 vaccine is a safer choice. Experts are working to learn more about both natural immunity and vaccine-induced immunity. 

Question: Can you share some information about the Janssen (Johnson & Johnson) vaccine?

Answer: This vaccine is slightly less effective than others in preventing mild disease but is very effective in preventing severe disease or death. The studies of this vaccine were carried out in the U.S., Africa and Brazil where the new variant strains are circulating. Although some people became mildly ill, no one was hospitalized and there were no deaths.